Introduction of SLC6A11
SLC6A11 is encoded by SLC6A11 gene. It belongs to the solute carrier family 6 which has been extensively studied during the past few decades because it offers numerous possibilities for therapeutic applications. It is a gamma-aminobutyric acid (GABA) transporter which can remove GABA to synaptic cleft. Meanwhile, many studies conducted on SLC6A11 show that it is related to various diseases, such as epilepsy, tricuspid valve stenosis and pulmonary valve insufficiency.
|Basic Information of SLC6A11|
|Protein Name||Sodium- and chloride-dependent GABA transporter 3|
|Organism||Homo sapiens (Human)|
Function of SLC6A11 Membrane Protein
SLC6A11, also named as GABA transporter 3, is a member of the main inhibitory transmitter in the brain. It can mainly express in brain, esophagus, and skin. Recent studies have indicated that SLC6A11 defects are strongly associated with various epilepsy, behavioral or intellectual issues. In addition, research has confirmed several SLC6A11 variants could be used as mediators in rat brain, and play an important role in clinical therapy.
Fig.1 The function of gamma-aminobutyric acid.
Application of SLC6A11 Membrane Protein in Literature
This article reports the relationship between SLC6A11 mutations and language delay and drug resistant epilepsy. These results indicate no relationship between its variants and antiepileptic drugs epilepsy in Chinese Han population.
This article analyzes the expression level of SLC6A11 in a [(3)H]GABA uptake assay. The results show that a novel series of compounds could be used as potent GAT3 inhibitors.
Authors in this group identify GABA transporters play an important role in regulating guanidinoacetate transport in rat brain by using primary astrocyte cultures and Chinese hamster ovary (CHO) cells expressing. The data suggest GAT2/Slc6a13 and GAT3/Slc6a11 can be regarded as mediators in rat brain.
This article focuses on the localization and expression of GABA transporters (GATs) in the suprachiasmatic hypothalamic nucleus (SCN). The data demonstrate that astrocytes expressing of GATs may regulate the extracellular GABA in SCN.
This article conducts a case-control study to detect the role of chromosome region 3p25.3 of SLC6A11 and SLC6A1 in patients who suffer from epilepsy and stereotypic behavior. The data illustrate that 3p25.3 microdeletion of GABA transporters SLC6A11 and SLC6A1 may have a significant effect on the epilepsy risk.
SLC6A11 Preparation Options
To obtain the soluble and functional target protein, the versatile Magic™ membrane protein production platform in Creative Biolabs enables many flexible options, from which you can always find a better match for your particular project. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-SLC6A11 antibody development services.
As a forward-looking research institute as well as a leading custom service provider in the field of membrane protein, Creative Biolabs has won good reputation among our worldwide customers for successfully accomplishing numerous challenging projects including generation of many functional membrane proteins. Please feel free to contact us for more information.